It can't hurt to ask; a patient-centered quality of service assessment of health canada's medical cannabis policy and program

Harm Reduction Journal

Philippe Lucas¹ 

[1] Center for Addictions Research of BC, University of Victoria, Technology Enterprise Facility, Room 273, 2300 McKenzie Ave, Victoria, BC, V8P 5C2, Canada

关键词: cannabis dispensary;    Health Canada;    Marihuana Medical Access Regulations;    medical cannabis;   

Others  :  810075
DOI  :  10.1186/1477-7517-9-2

 received in 2011-08-26, accepted in 2012-01-03,  发布年份 2012

【 摘 要 】

Background

In 2001 Health Canada responded to a series of Ontario court decisions by creating the Marihuana Medical Access Division (MMAD) and the Marihuana Medical Access Regulations (MMAR). Although Health Canada has conducted a small number of stakeholder consultations, the federal government has never polled federally authorized cannabis patients. This study is an attempt to learn more about patient needs, challenges and experiences with the MMAD.

Methods

Launched in the spring of 2007, Quality of Service Assessment of Health Canada's Medical Cannabis Policy and Program pairs a 50 question online survey addressing the personal experiences of patients in the federal cannabis program with 25 semi-guided interviews. Data gathering for this study took place from April 2007 to Jan. 2008, eventually garnering survey responses from 100 federally-authorized users, which at the time represented about 5% of the patients enrolled in Health Canada's program. This paper presents the results of the survey portion of the study.

Results

8% of respondents report getting their cannabis from Health Canada, while 66% grow it for themselves. >50% report that they frequent compassion clubs or dispensaries, which remain illegal and unregulated in Canada. 81% of patients would chose certified organic methods of cultivation; >90% state that not all strains are equally effective at relieving symptoms, and 97% would prefer to obtain cannabis from a source where multiple strains are available. Of the 48 patients polled that had tried the Health Canada cannabis supply, >75% rank it as either "1" or "2" on a scale of 1-10 (with "1" being "very poor", and 10 being "excellent").

Discussion

72% of respondents report they are either "somewhat" or "totally unsatisfied" with Canada's medical cannabis program. These survey results and relevant court decisions suggest that the MMAR are not meeting the needs of most of the nation's medical cannabis patient community. It is hoped this research will help inform policy changes that will better address the needs of Canada's critically and chronically ill medical cannabis patient population, including the integration of community-based dispensaries into this novel healthcare delivery model.

【 授权许可】

   
2012 Lucas; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]United Nations Office for Drug Control and Crime Prevention: World Drug Report 2001. Oxford: Oxford University Press; 2001:-30.
• [2]Grinspoon L, Bakalar JB: Marijuana the Forbidden Medicine. New Haven, CT: Yale University Press; 1993.
• [3]Lucas P: Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice. International Journal of Drug Policy 2009, 20:296-303.
• [4]Lucas P: Regulating compassion; an overview of Health Canada's medical cannabis policy and practice. Harm Reduction Journal 2008, 5:5. BioMed Central Full Text
• [5]Belle-Isle L, Hathaway A: Barriers to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care 2007, 19(4):500-506.
• [6]Belle-Isle L: Cannabis as Therapy for People Living With HIV/AIDS; Our Right, Our Choice. Canadian AIDS Society 2006. Retrieved August 11th 2011 from: http://www.cdnaids.ca/files.nsf/pages/cannabis_english/$file/cannabis_english.pdf webcite
• [7]Reiman A: Self-efficacy, social support and service integration at medical cannabis facilities in the San Francisco Bay area of California. Health and Social Care in the Community 2008, 18(1):31-41.
• [8]Canadian Association of Medical Cannabis Dispensaries press release Retrieved August 10, 2011; http://www.camcd-acdcm.ca/2011/07/patients-hc-recognize-dispensaries/ webcite
• [9]Fankhauser M, In F Grotenhermen, Russo E (Eds): Cannabis and Cannabinoids New York: The Hayward Integrative Press; 2002:37.
• [10]Shaughnessy WBO: Trans Med Phys Soc Bengal. 1840, 71-102:421-461.
• [11]Von Bibra E: Die Narkotischen Genussmittel und der Mensch. Nuremberg; 1855:290.
• [12]Murphy E: The Black Candle. Toronto. Coles Publishing; 1973.
• [13]Russo EB: History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Chemistry and Biodiversity 2007, 4:1614-1648.
• [14]Hazekamp A, Grotenhermen F: Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010, 5(special):1-21.
• [15]Ben Amar M: Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006, 105(1-2):1-25.
• [16]Grotenhermen F, Russo E: Cannabis and Cannabinoids. New York: The Haworth Press; 2002.
• [17]Blume L, Bass C, Childers S, Dalton G, Richardson J, Selley D, Xiao R, Howlett A: Cannabinoid receptor interacting protein 1A (CRIP1A) modulates striatal neuropharmacology and signal transduction in cannabinoid, dopamine and opioid receptor systems. In 21st Annual Symposium on the Cannabinoids. International Cannabinoid Research Society, Research Triangle Park, NC, USA; 2011:P2-21.
• [18]Ramesh D, Owens R, Kinsey S, Cravatt B, Sim-Selley L, Lichtman A: Effects of chronic manipulation of the endocannabinoid system on precipitated opioid withdrawal. In 21st Annual Symposium on the Cannabinoids. International Cannabinoid Research Society, Research Triangle Park, NC, USA; 2011:3-22.
• [19]Reinarman C, Nunberg H, Lanthier F, Heddleston T: Who are medical marijuana patients? Population characteristics from nine California assessment Clinics. Journal of Psychoative Drugs 2011, 43(2):128-135.
• [20]Reiman A: Cannabis as a substitute for alcohol and other drugs. Harm Reduction Journal 2009, 6:35. BioMed Central Full Text
• [21]Health Canada website: Medical Use of Marihuana. Retrieved Aug. 18th, 2011 http://www.hc-sc.gc.ca/dhp-mps/marihuana/stat/_2010/jan-eng.php webcite
• [22]Nolin PC, Kenny C, Banks T, Maheu S, Rossiter E: Report of the Senate Special Committee on Illegal Drugs. Ottawa: Senate of Canada; 2002.
• [23]Canadian Medical Association: CMA asks government - where is the evidence to support your interim policy on the provision of marijuana for medical purposes? Retrieved Aug. 16th, 2011 http://www.cma.ca/index.cfm/ci_id/9347/la_id/1.htm webcite
• [24]Grinspoon L: Medical marijuana in a time of prohibition. International Journal of Drug Policy 1999, 10:145-156.
• [25]Los Angeles Times: No quick action seen on L.A. marijuana dispensaries. Retrieved on August 6th 2011 http://www.latimes.com/news/local/la-me-medical-marijuana4-2009nov04,0,4490002.story webcite
• [26]Gieringer D: 10th Anniversary of Prop. 215; California Leads, Feds Still Lag on Medical Marijuana. Oakland, CA; Retrieved August 15th from California NORML website: http://canorml.org webcite
• [27]Statistics Canada: 2006 Census. Retrieved Aug 18, 2011 http://www40.statcan.ca/l01/cst01/educ43a-eng.htm webcite
• [28]Hashibe M, et al.: Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006, 1829-34.
• [29]Ware MA, Ducruet T, Robinson AR: Evaluation of herbal cannabis characteristics by medical users: a randomized trial. Harm Reduct J 2006, 3(32):1-6.
• [30]Health Canada website: Proposed Improvements to Health Canada's Marihuana Medical Access Program. Retrieved January 12th, 2011 http://www.hc-sc.gc.ca/dhp-mps/consultation/marihuana/_2011/program/consult-eng.php webcite